



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)

(Company Registration Number: 201134046D)

DISCLAIMER OF OPINION BY THE EXTERNAL AUDITORS ON THE GROUP'S AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025

Pursuant to Rule 704(4) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited ("SGX-ST") ("Catalist Rules"), the Board of Directors (the "Board") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "Company" and together with its subsidiaries, collectively, the "Group") wishes to announce that the External Auditors of the Company, Messrs Foo Kon Tan LLP (the "External Auditors"), has in its Independent Auditors' Report dated 9 October 2025, issued a disclaimer of opinion ("Disclaimer Opinion") on the consolidated audited financial statements of the Company and the Group for the financial year ended 30 June 2025 ("FY2025") (the "Independent Auditors' Report").

The basis for the Disclaimer Opinion, an extract of which is set out in Appendix A of this announcement, will be contained in the Independent Auditors' Report and is based on, *inter alia*, the following considerations:

A. Opening balances and comparative information and the financial effect on the current year's figures

The External Auditors were appointed as auditor of the Group and the Company on 5 February 2025, in respect of the financial statements for the financial year ended 30 June 2025 ("FY2025"). The financial statements for the financial year ended 30 June 2024 ("FY2024") were audited by another auditor who expressed a disclaimer of opinion on those financial statements on 9 December 2024.

The basis for a disclaimer of opinion by the predecessor auditor relates to the use of going concern assumption, impairment of property, plant and equipment, and impairment of the Company's other receivables from a subsidiary.

The predecessor auditor was unable to obtain sufficient appropriate audit evidence that the use of going concern assumption in preparation of the financial statements was appropriate, the appropriateness of recoverable amount of the Group's property, plant and equipment and the Company's other receivables from a subsidiary as at 30 June 2024.

The External Auditors are unable to obtain sufficient appropriate audit evidence to determine whether the opening balances in respect of property, plant and equipment and the Company's other receivables from a subsidiary as at 1 July 2024 are appropriately stated. Due to the carry-forward effects on the financial performance, equity changes and cash flows for the year ended 30 June 2025 and the closing balances of assets and liabilities of the Group and the Company as at 30 June 2025, the External Auditors are unable to determine whether any adjustments might have been necessary in respect of the financial statements for FY2025.

In addition, the current year's financial statements may not be comparable to the previous year's financial statements because of these matters.

B. Going Concern

As described in Note 2.2 to the financial statements, for the financial year ended 30 June 2025, the Group reported a loss after tax of \$27,046,778 from continuing operations and net cash used in operating activities amounted to \$10,650,389. As at 30 June 2025, the Group's and the

Company's current liabilities exceeded its current assets by \$12,034,424 and \$3,974,314 respectively.

As at 30 June 2025, the Company's total assets include an investment in a subsidiary, Proton Therapy Pte. Ltd. ("PTPL"), of \$153,175,528 (Note 9(a)) which accounts for approximately 95% of the Company's total assets. This subsidiary reported a loss after tax of \$19,630,487 and net cash used in operating activities of \$10,203,087 for the financial year ended 30 June 2025, and its current liabilities exceeded its current assets by \$5,539,338 as at 30 June 2025. The Company is dependent on the cash flows from this subsidiary to discharge its liabilities as and when they fall due.

These conditions above indicate the existence of material uncertainties that may cast significant doubt on the ability of the Group and of the Company to continue as going concerns.

Notwithstanding this, as disclosed in Note 2.2 to the financial statements, the accompanying financial statements have been prepared on a going concern basis as a result of certain key assumptions that have been made which are dependent on the outcome of certain future events which cannot be determined as of the date of this report. These include the ability of the Company to draw down on the financial support and extend, capitalise or repay loans, and the ability of the Group to significantly increase its business, including the main radiation therapy business of its subsidiary. The External Auditors have been unable to obtain sufficient appropriate audit evidence to enable us to conclude on the appropriateness of management's use of the going concern assumption in its preparation of the accompanying financial statements.

If the going concern assumption is not appropriate, adjustments will need to be made to reflect a situation where the assets may need to be realised other than in the normal course of business and at amounts which could be significantly different from the amounts stated in the statement of financial position of the Group and statement of financial position of the Company. As a result, the Group and the Company may have to provide for further liabilities which may arise, and to classify the non-current assets and non-current liabilities to current assets and current liabilities respectively. The financial statements do not include the adjustments that would result in the event the Group and Company are unable to continue as going concerns.

C. Impairment of property, plant and equipment

As disclosed in Note 4(a) to the financial statements, as at 30 June 2025, there were indicators of impairment of property, plant and equipment based on evidence from internal reporting that the economic performance of each cash generating unit ("CGU") of the Group was worse than expected. As at 30 June 2025, the carrying amounts of property, plant and equipment of the Group amounted to \$116,194,098, of which \$112,055,788 (Note 4(a)) relates to property, plant and equipment of the radiation therapy services CGU.

Based on the impairment assessment performed, management has determined that no impairment charge is required to be recognised on the carrying amount of its property, plant and equipment of the radiation therapy services CGU as at 30 June 2025.

The External Auditors are unable to obtain sufficient appropriate audit evidence regarding the reasonableness of certain key assumptions used in the determination of the recoverable amount of the radiation therapy services CGU, in particular, the forecast revenue of proton beam therapy and photon radiation therapy services over the period of the forecast.

Consequently, the External Auditors are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the property, plant and equipment is necessary.

D. Impairment of the Company's investment in a subsidiary

As disclosed in Note 9 to the financial statements, as at 30 June 2025, there were indicators of impairment of cost of investment in subsidiaries based on evidence from internal reporting that the economic performance of each CGU of the Group was worse than expected. The carrying amounts of cost of investment in subsidiaries of the Company amounted to \$154,435,528 as at

30 June 2025, of which \$153,175,528 (Note 9(a)) relates to cost of investment in a subsidiary, PTPL, which is the radiation therapy services CGU.

Based on the impairment assessment performed, management has determined that no impairment charge is required to be recognised on the carrying amount of its investment in subsidiary, PTPL, as at 30 June 2025.

The External Auditors are unable to obtain sufficient appropriate audit evidence regarding the reasonableness of certain key assumptions used in the determination of the recoverable amount of the radiation therapy services CGU, in particular, the forecast revenue of proton beam therapy and photon radiation therapy services over the period of the forecast.

Consequently, the External Auditors are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the cost of investment in subsidiaries relating to PTPL is necessary.

The Board is of the opinion that the use of the going concern assumption is appropriate taking into consideration, *inter alia*, the following grounds, as disclosed in the Company's announcement dated 29 August 2025 relating to the full-year results in respect of the financial year ended 30 June 2025 (the **"FY2025 Full Yearly Results"**):

- the Group has drawn down loans from a subsidiary of the controlling shareholder for a total of S\$3 million subsequent to the financial year end;
- the Group will be able to obtain further financial support from a subsidiary of the controlling shareholder and a director for collectively up to S\$6 million subsequent to the financial year end, subject to the necessary approvals;
- the Company is in the process of converting the existing \$5,000,000 loan from a non-related party, including accrued interest by way of equity conversion as announced in September 2025, subject to regulatory approvals;
- the Company expects to convert the existing \$2,000,000 loan from a subsidiary of the controlling shareholder into equity, subject to regulatory approvals;

In addition to the above, the Board wishes to clarify that the nature of the impairment of the PPE, if any, will not have an impact on the Group's cash flows. The cost of investment in the subsidiary is eliminated on consolidation and will not have any impact on the Group's financial statements.

If the above-mentioned support comes through and if the management's expectations of patient and project flows materialise, the Board of Directors concurs with the management that the Company has no going concern issues. The Board of Directors also confirms that, to the best of its knowledge, all material disclosures have been provided for trading of the Company's securities in an orderly manner.

Shareholders and potential investors of the Company are advised to read this announcement in conjunction with the Company's Annual Report in respect of FY2025 in its entirety.

Please refer to Appendix A of this announcement for the basis of the Disclaimer Opinion contained in the Independent Auditors' Report of the Company and the Group for FY2025.

The Independent Auditors' Report and consolidated audited financial statements for FY2025 will form part of the Company's Annual Report in respect of FY2025 which will be released on SGXNet on or before 13 October 2025.

Shareholders and potential investors are advised to exercise caution before making any decision in respect of their dealings in the Company's shares. Shareholders and potential investors who are in any doubt about this announcement should consult their stockbroker, bank manager, solicitor, or another professional adviser.

The Company will make further announcements on any material updates in relation to the above, as and when appropriate.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
9 October 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Appendix A

Independent Auditors' Report for the Financial Year ended 30 June 2025

Independent Auditor's Report

Members of the Company
Singapore Institute of Advanced Medicine Holdings Ltd.

Report on the audit of the financial statements

Disclaimer of Opinion

We were engaged to audit the financial statements of Singapore Institute of Advanced Medicine Holdings Ltd. (the "Company") and its subsidiaries (the "Group"), which comprise:

- the consolidated statement of financial position of the Group as at 30 June 2025;
- the statement of financial position of the Company as at 30 June 2025;
- the consolidated statement of comprehensive income of the Group for the financial year then ended;
- the consolidated statement of changes in equity of the Group for the financial year then ended;
- the consolidated statement of cash flows of the Group for the financial year then ended; and
- the notes to the financial statements, including material accounting policy information.

We do not express an opinion on the accompanying consolidated financial statements of the Group and the statement of financial position of the Company. Because of the significance of the matters described in the Basis for Disclaimer of Opinion section of our report, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.

Basis for Disclaimer of Opinion

(i) Opening balances and comparative information and the financial effect on the current year's figures

We were appointed as auditor of the Group and the Company on 5 February 2025, in respect of the financial statements for the financial year ended 30 June 2025 ("FY2025"). The financial statements for the financial year ended 30 June 2024 ("FY2024") were audited by another auditor who expressed a disclaimer of opinion on those financial statements on 9 December 2024.

The basis for a disclaimer of opinion by the predecessor auditor relates to the use of going concern assumption, impairment of property, plant and equipment, and impairment of the Company's other receivables from a subsidiary.

The predecessor auditor was unable to obtain sufficient appropriate audit evidence that the use of going concern assumption in preparation of the financial statements was appropriate, the appropriateness of recoverable amount of the Group's property, plant and equipment and the Company's other receivables from a subsidiary as at 30 June 2024.

We are unable to obtain sufficient appropriate audit evidence to determine whether the opening balances in respect of property, plant and equipment and the Company's other receivables from a subsidiary as at 1 July 2024 are appropriately stated. Due to the carry-forward effects on the financial performance, equity changes and cash flows for the year ended 30 June 2025 and the closing balances of assets and liabilities of the Group and the Company as at 30 June 2025, we are unable to determine whether any adjustments might have been necessary in respect of the financial statements for FY2025.

In addition, the current year's financial statements may not be comparable to the previous year's financial statements because of these matters.

(ii) Going concern

As described in Note 2.2 to the financial statements, for the financial year ended 30 June 2025, the Group reported a loss after tax of \$27,046,778 from continuing operations and net cash used in operating activities amounted to \$10,650,389. As at 30 June 2025, the Group's and the Company's current liabilities exceeded its current assets by \$12,034,424 and \$3,974,314 respectively.

As at 30 June 2025, the Company's total assets include an investment in a subsidiary, Proton Therapy Pte. Ltd. ("PTPL"), of \$153,175,528 (Note 9(a)) which accounts for approximately 95% of the Company's total assets. This subsidiary reported a loss after tax of \$19,630,487 and net cash used in operating activities of \$10,203,087 for the financial year ended 30 June 2025, and its current liabilities exceeded its current assets by \$5,539,338 as at 30 June 2025. The Company is dependent on the cash flows from this subsidiary to discharge its liabilities as and when they fall due.

These conditions above indicate the existence of material uncertainties that may cast significant doubt on the ability of the Group and of the Company to continue as going concerns.

Notwithstanding this, as disclosed in Note 2.2 to the financial statements, the accompanying financial statements have been prepared on a going concern basis as a result of certain key assumptions that have been made which are dependent on the outcome of certain future events which cannot be determined as of the date of this report. These include the ability of the Company to draw down on the financial support and extend, capitalise or repay loans, and the ability of the Group to significantly increase its business, including the main radiation therapy business of its subsidiary. We have been unable to obtain sufficient appropriate audit evidence to enable us to conclude on the appropriateness of management's use of the going concern assumption in its preparation of the accompanying financial statements.

If the going concern assumption is not appropriate, adjustments will need to be made to reflect a situation where the assets may need to be realised other than in the normal course of business and at amounts which could be significantly different from the amounts stated in the statement of financial position of the Group and statement of financial position of the Company. As a result, the Group and the Company may have to provide for further liabilities which may arise, and to classify the non-current assets and non-current liabilities to current assets and current liabilities respectively. The financial statements do not include the adjustments that would result in the event the Group and Company are unable to continue as going concerns.

(iii) Impairment of property, plant and equipment

As disclosed in Note 4(a) to the financial statements, as at 30 June 2025, there were indicators of impairment of property, plant and equipment based on evidence from internal reporting that the economic performance of each cash generating unit ("CGU") of the Group was worse than expected. As at 30 June 2025, the carrying amounts of property, plant and equipment of the Group amounted to \$116,194,098, of which \$112,055,788 (Note 4(a)) relates to property, plant and equipment of the radiation therapy services CGU.

Based on the impairment assessment performed, management has determined that no impairment charge is required to be recognised on the carrying amount of its property, plant and equipment of the radiation therapy services CGU as at 30 June 2025.

We are unable to obtain sufficient appropriate audit evidence regarding the reasonableness of certain key assumptions used in the determination of the recoverable amount of the radiation therapy services CGU, in particular, the forecast revenue of proton beam therapy and photon radiation therapy services over the period of the forecast.

Consequently, we are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the property, plant and equipment is necessary.

(iv) Impairment of the Company's investment in a subsidiary

As disclosed in Note 9 to the financial statements, as at 30 June 2025, there were indicators of impairment of cost of investment in subsidiaries based on evidence from internal reporting that the economic performance of each CGU of the Group was worse than expected. The carrying amounts of cost of investment in subsidiaries of the Company amounted to \$154,435,528 as at 30 June 2025, of which \$153,175,528 (Note 9(a)) relates to cost of investment in a subsidiary, PTPL, which is the radiation therapy services CGU.

Based on the impairment assessment performed, management has determined that no impairment charge is required to be recognised on the carrying amount of its investment in subsidiary, PTPL, as at 30 June 2025.

We are unable to obtain sufficient appropriate audit evidence regarding the reasonableness of certain key assumptions used in the determination of the recoverable amount of the radiation therapy services CGU, in particular, the forecast revenue of proton beam therapy and photon radiation therapy services over the period of the forecast.

Consequently, we are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the cost of investment in subsidiaries relating to PTPL is necessary.

Other Matter

The financial statements of the Group and the Company for the financial year ended 30 June 2024 were audited by another auditor who expressed a disclaimer of opinion on those statements on 9 December 2024 in relation to the use of going concern assumption, impairment of property, plant and equipment, and impairment of the Company's other receivables from a subsidiary.

Responsibilities of Management and Directors for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Companies Act 1967 ("the Act") and Singapore Financial Reporting Standards (International), and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our responsibility is to conduct an audit of the financial statements in accordance with Singapore Standards on Auditing and to issue an auditor's report. However, because of the matters described in the Basis for Disclaimer of Opinion section of our report, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.

We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code.

Report on Other Legal and Regulatory Requirements

In view of the significance of the matters referred to in the Basis for Disclaimer Opinion section of our report, we do not express an opinion on whether the accounting and other records required by the Act to be kept by the Company and by those subsidiary corporations incorporated in Singapore of which we are the auditors have been properly kept in accordance with provisions of the Act.

The engagement partner on the audit resulting in this independent auditor's report is Ho Teik Tiong.

Foo Kon Tan LLP
Public Accountants and
Chartered Accountants

Singapore,
9 October 2025